Tempus AI Got an $80 Target and 28% Upside Call. Is Wall Street Underestimating Its Healthcare Data Moat?

On September 2, Cantor Fitzgerald initiated coverage of Tempus AI with an Overweight rating and an $80 price target, implying a potential 28% upside from the current price. The company's unique value proposition lies in its integration of clinical data, diagnostics, software, and artificial intelligence within healthcare workflows. Unlike a mere data platform, Tempus AI now faces expectations to demonstrate durable profit generation.

Tempus AI's financial performance has been impressive. Second-quarter revenue grew by 22% year-over-year to $382.5 million, with notable increases in oncology testing volume (31%), data licensing and modeling revenue (36%), and new data and applications licenses worth roughly $200 million. Management raised full-year revenue guidance to $1.595 billion to $1.605 billion, indicating approximately 25% growth, which bolsters confidence in the bullish target.

However, the company's growth story is accompanied by significant challenges. Healthcare data is subject to stringent regulations, costly curation, and dependent on payer reimbursement and customer renewal behavior. Moreover, Tempus AI is expanding through acquisitions, such as its agreement to purchase Personalis, which could lead to integration costs, dilution, and changing test economics that might delay the anticipated operating leverage.

Despite these risks, the bullish target remains a compelling estimate. Hedge funds have taken notice, with 38 funds holding positions in Tempus AI at the end of Q2, up from 33 in Q1, with ARK Investment Management significantly increasing its stake. Yet, skepticism persists, as evidenced by a short-interest of 29.87 million shares, representing 29.91% of the reported float and with only 7.25 days to cover.

The true test for Tempus AI is whether its healthcare data moat can produce repeatable margins before the market's elevated expectations and acquisition risks catch up. The strength of the moat hinges on the continuous improvement of the dataset through more clinical interactions, making the platform more valuable to researchers and physicians. Conversely, if customers can access comparable data more affordably or if privacy restrictions impede data reuse, the moat could weaken.

While the potential of Tempus AI as an investment is acknowledged, there is a belief that other AI stocks may offer greater upside potential with less downside risk. For those seeking an extremely undervalued AI stock that could benefit from the Trump-era tariffs and the onshoring trend, an alternative investment option is suggested in the form of a free report.